Guillain–Barré syndrome associated with COVID-19: A systematic review
With the outbreak of coronavirus disease 2019 (COVID-19), the whole world was impacted by a pandemic. With the passage of time and knowledge about the dynamics and viral propagation of this disease, the short-, medium- and long-term repercussions are still being discovered. During this period, it ha...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Brain, Behavior, & Immunity - Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666354622001685 |
| _version_ | 1828000749398786048 |
|---|---|
| author | Vitória Pimentel Vanessa Wallau Luchsinger Gabriel Leal Carvalho Allan Marinho Alcará Nathalia Bianchini Esper Daniel Marinowic Gabriele Zanirati Jaderson Costa da Costa |
| author_facet | Vitória Pimentel Vanessa Wallau Luchsinger Gabriel Leal Carvalho Allan Marinho Alcará Nathalia Bianchini Esper Daniel Marinowic Gabriele Zanirati Jaderson Costa da Costa |
| author_sort | Vitória Pimentel |
| collection | DOAJ |
| description | With the outbreak of coronavirus disease 2019 (COVID-19), the whole world was impacted by a pandemic. With the passage of time and knowledge about the dynamics and viral propagation of this disease, the short-, medium- and long-term repercussions are still being discovered. During this period, it has been learned that various manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can affect the nervous system. In recent months, a variety of studies and case reports have proposed an association between COVID-19 and Guillain–Barré syndrome (GBS). The present work aims to systematically review the publications available to date to verify the relationship between these two pathologies and the characteristics of post-COVID GBS. There were 156 studies included in this work, resulting in a total of 436 patients. The findings show a mean age of the patients of 61,38 years and a male majority. The GBS symptoms began on average 19 days after the onset of COVID-19 infection. Regarding GBS, the main manifestations found included generalized weakness, reflex reduction, facial paresis/paralysis and hypoesthesia. As expected, the most common result in cerebrospinal fluid (CSF) analysis was albuminocytological dissociation. A pattern of blood analysis findings common to all patients was not observed due to non-standardization of case reports. Regarding electrodiagnostic studies, acute inflammatory demyelinating polyneuropathy (AIDP) appeared as the most common subtype of GBS in this study. There have been reports, to a lesser extent, of acute motor axonal neuropathy (AMAN), acute sensorimotor axonal neuropathy (AMSAN), the pharyngeal-cervical-brachial variant (PCB), and Miller-Fisher syndrome (MFS). The GBS treatment used was mainly intravenous immunoglobulin (IVIG) and plasma exchange (PLEX). Therefore, the present study reports a high prevalence of hospitalization and intensive care units ICU admissions, conjecturing a relationship between the development of GBS and the severity of COVID-19. Despite the severity, most patients showed improvement in GBS symptoms after treatment, and their residual symptoms did not include motor involvement. Therefore, the development of GBS seems to be related to COVID-19 infection, as reported by the present systematic review. |
| first_indexed | 2024-04-10T06:19:02Z |
| format | Article |
| id | doaj.art-f770392247fc4f40927af27e98cb6115 |
| institution | Directory Open Access Journal |
| issn | 2666-3546 |
| language | English |
| last_indexed | 2024-04-10T06:19:02Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Brain, Behavior, & Immunity - Health |
| spelling | doaj.art-f770392247fc4f40927af27e98cb61152023-03-02T05:03:09ZengElsevierBrain, Behavior, & Immunity - Health2666-35462023-03-0128100578Guillain–Barré syndrome associated with COVID-19: A systematic reviewVitória Pimentel0Vanessa Wallau Luchsinger1Gabriel Leal Carvalho2Allan Marinho Alcará3Nathalia Bianchini Esper4Daniel Marinowic5Gabriele Zanirati6Jaderson Costa da Costa7Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Undergraduate Research Program, School of Medicine and Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilBrain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Undergraduate Research Program, School of Medicine and Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilBrain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Undergraduate Research Program, School of Medicine and Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, BrazilBrain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Graduate Program in Medicine and Health Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, BrazilBrain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Center for the Developing Brain, Child Mind Institute, New York, NY, USABrain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Graduate Program in Medicine and Health Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; Graduate Program in Medicine, Pediatrics and Child Health, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, BrazilBrain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Graduate Program in Medicine and Health Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, BrazilBrain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil; Graduate Program in Medicine and Health Sciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; Graduate Program in Medicine, Pediatrics and Child Health, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil; Corresponding author. Pontifical Catholic University of Rio Grande do Sul (PUCRS), 90619-900, Jd. Botânico, Porto Alegre, Rio Grande do Sul, Brazil.With the outbreak of coronavirus disease 2019 (COVID-19), the whole world was impacted by a pandemic. With the passage of time and knowledge about the dynamics and viral propagation of this disease, the short-, medium- and long-term repercussions are still being discovered. During this period, it has been learned that various manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can affect the nervous system. In recent months, a variety of studies and case reports have proposed an association between COVID-19 and Guillain–Barré syndrome (GBS). The present work aims to systematically review the publications available to date to verify the relationship between these two pathologies and the characteristics of post-COVID GBS. There were 156 studies included in this work, resulting in a total of 436 patients. The findings show a mean age of the patients of 61,38 years and a male majority. The GBS symptoms began on average 19 days after the onset of COVID-19 infection. Regarding GBS, the main manifestations found included generalized weakness, reflex reduction, facial paresis/paralysis and hypoesthesia. As expected, the most common result in cerebrospinal fluid (CSF) analysis was albuminocytological dissociation. A pattern of blood analysis findings common to all patients was not observed due to non-standardization of case reports. Regarding electrodiagnostic studies, acute inflammatory demyelinating polyneuropathy (AIDP) appeared as the most common subtype of GBS in this study. There have been reports, to a lesser extent, of acute motor axonal neuropathy (AMAN), acute sensorimotor axonal neuropathy (AMSAN), the pharyngeal-cervical-brachial variant (PCB), and Miller-Fisher syndrome (MFS). The GBS treatment used was mainly intravenous immunoglobulin (IVIG) and plasma exchange (PLEX). Therefore, the present study reports a high prevalence of hospitalization and intensive care units ICU admissions, conjecturing a relationship between the development of GBS and the severity of COVID-19. Despite the severity, most patients showed improvement in GBS symptoms after treatment, and their residual symptoms did not include motor involvement. Therefore, the development of GBS seems to be related to COVID-19 infection, as reported by the present systematic review.http://www.sciencedirect.com/science/article/pii/S2666354622001685Guillain–BarréMiller-FisherCOVID-19SARS-CoV-2Peripheral nervous system |
| spellingShingle | Vitória Pimentel Vanessa Wallau Luchsinger Gabriel Leal Carvalho Allan Marinho Alcará Nathalia Bianchini Esper Daniel Marinowic Gabriele Zanirati Jaderson Costa da Costa Guillain–Barré syndrome associated with COVID-19: A systematic review Brain, Behavior, & Immunity - Health Guillain–Barré Miller-Fisher COVID-19 SARS-CoV-2 Peripheral nervous system |
| title | Guillain–Barré syndrome associated with COVID-19: A systematic review |
| title_full | Guillain–Barré syndrome associated with COVID-19: A systematic review |
| title_fullStr | Guillain–Barré syndrome associated with COVID-19: A systematic review |
| title_full_unstemmed | Guillain–Barré syndrome associated with COVID-19: A systematic review |
| title_short | Guillain–Barré syndrome associated with COVID-19: A systematic review |
| title_sort | guillain barre syndrome associated with covid 19 a systematic review |
| topic | Guillain–Barré Miller-Fisher COVID-19 SARS-CoV-2 Peripheral nervous system |
| url | http://www.sciencedirect.com/science/article/pii/S2666354622001685 |
| work_keys_str_mv | AT vitoriapimentel guillainbarresyndromeassociatedwithcovid19asystematicreview AT vanessawallauluchsinger guillainbarresyndromeassociatedwithcovid19asystematicreview AT gabriellealcarvalho guillainbarresyndromeassociatedwithcovid19asystematicreview AT allanmarinhoalcara guillainbarresyndromeassociatedwithcovid19asystematicreview AT nathaliabianchiniesper guillainbarresyndromeassociatedwithcovid19asystematicreview AT danielmarinowic guillainbarresyndromeassociatedwithcovid19asystematicreview AT gabrielezanirati guillainbarresyndromeassociatedwithcovid19asystematicreview AT jadersoncostadacosta guillainbarresyndromeassociatedwithcovid19asystematicreview |